Bossmar T, Akerlund M, Szamatowicz J, Laudanski T, Fantoni G, Maggi M
Department of Obstetrics and Gynaecology, University Hospitals of Lund, Sweden.
Br J Obstet Gynaecol. 1995 Nov;102(11):907-12. doi: 10.1111/j.1471-0528.1995.tb10880.x.
To study in nonpregnant women myometrial actions of vasopressin and oxytocin and the involvement in these effects of specific uterine receptors.
Twenty-eight women undergoing hysterectomy for benign gynaecological disorders.
Intrauterine pressure recordings. Intravenous bolus injections of 10 pmol/kg body weight of vasopressin and oxytocin. Repeated blood sampling for measurement of vasopressin and oxytocin concentrations in plasma. Recording of effects of vasopressin and oxytocin on isolated myometrium. Estimation of myometrial concentrations of vasopressin V1a and oxytocin receptors. Measurement of plasma oestradiol and progesterone.
Vasopressin- and oxytocin-induced increases of the area under the in vivo recording curve over 10 minutes and EC50 concentrations of dose-responses in vitro. Concentrations of vasopressin V1a and oxytocin receptors.
Vasopressin was on average four times more potent than oxytocin in vivo. The effect of vasopressin premenstrually was more pronounced than in women under oestrogen influence only (proliferative phase-hyperproliferation; P = 0.02), and tended to be more marked than in those in the luteal phase (P = 0.07). No significant variation in oxytocin response with the hormonal state was observed. EC50 concentrations of vasopressin were more than 20 times lower than those of oxytocin. The median concentration of the vasopressin V1a receptor was 208 (range 139-343) fmol/mg protein and that of the oxytocin receptor 49 (38-87) fmol/mg protein. Vasopressin receptor concentrations and in vivo effects of this peptide did not correlate, whereas for those of oxytocin a significant correlation was observed (P = 0.02).
The high potency of vasopressin in nonpregnant women, particularly premenstrually, firmly supports an aetiological importance of this peptide in the uterine hyperactivity of primary dysmenorrhoea. Oxytocin seems to be less important in this condition in view of its much smaller potency and the absence of increase in effect premenstrually. Vasopressin appears to influence both the oxytocin and the vasopressin V1a receptor sites in the uterus, whereas oxytocin acts specifically on its own receptor.
研究血管加压素和缩宫素对非妊娠女性子宫肌层的作用以及特定子宫受体在这些作用中的参与情况。
28名因良性妇科疾病接受子宫切除术的女性。
子宫内压力记录。静脉推注10 pmol/kg体重的血管加压素和缩宫素。多次采血以测量血浆中血管加压素和缩宫素的浓度。记录血管加压素和缩宫素对离体子宫肌层的作用。估计子宫肌层中血管加压素V1a受体和缩宫素受体的浓度。测量血浆雌二醇和孕酮水平。
血管加压素和缩宫素在体内记录曲线下10分钟内引起的面积增加以及体外剂量反应的半数有效浓度（EC50）。血管加压素V1a受体和缩宫素受体的浓度。
血管加压素在体内的效力平均比缩宫素高四倍。血管加压素在经前期的作用比仅受雌激素影响的女性（增殖期 - 过度增殖；P = 0.02）更明显，并且倾向于比黄体期的女性更显著（P = 0.07）。未观察到缩宫素反应随激素状态的显著变化。血管加压素的EC50浓度比缩宫素低20倍以上。血管加压素V1a受体的中位浓度为208（范围139 - 343）fmol/mg蛋白质，缩宫素受体的中位浓度为49（38 - 87）fmol/mg蛋白质。血管加压素受体浓度与该肽的体内作用不相关，而缩宫素的受体浓度与体内作用存在显著相关性（P = 0.02）。
血管加压素在非妊娠女性中效力高，尤其是在经前期，有力地支持了该肽在原发性痛经子宫活动亢进中的病因学重要性。鉴于缩宫素效力小得多且经前期作用无增加，其在这种情况下似乎不太重要。血管加压素似乎影响子宫中的缩宫素和血管加压素V1a受体位点，而缩宫素特异性作用于其自身受体。
